NCT06050252 2026-05-22Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before SurgeryNational Cancer Institute (NCI)Phase 2 Recruiting27 enrolled